

Cardiac MR Valve Assessment Study Report

CMR 2, PATIENT May 23, 2022

Accession/Encounter No: CV34800230

DOB: 1951-08-01 Age:

Gender:

70 in Height:

2.71 m² BSA: BMI:

44.34

Reading Group: Cardiac MR Reading Group

Study Time:

Referring Group: Emergency Physician

02:42 PM

Sonographer: meduser

Study Quality: Good

Final Impression:

1. BILEAFLET MITRAL VALVE PROLAPSE WITH MODERATE-SEVERE PRIMARY MR (rvol 56ML; RF 44%).

2. THERE IS AN ADDITIONAL LARGE PROLAPSE VOLUME OF 22 ML, WITH A POTENTIALLY SEVERE TOTAL MITRAL REGURGITANT LOAD OF 78 ML (52%).

Summary

Left Ventricle: Quantitative LVEF 68%. LV wall thickness is normal. LV cavity is mildmoderately enlarged (LVEDVi 125 mL/m2). LV Systolic function is normal. There is no LV mass/thrombus.

Viability: No evidence of myocardial infarction or scar.

Right Ventricle: Quantitative RVEF 54%. RV wall thickness is normal. RV cavity size is normal. RV systolic function is normal. There is no RV mass/thrombus.

Left Atrium: LA is severely enlarged (LAVi 115 mL/m2). There is no LA mass/thrombus.

Right Atrium: RA cavity size is enlarged. There is no RA mass/thrombus.

Weight: 309 lbs

Pericardium: Pericardium is normal in thickness. There is a small inferior and lateral pericardial effusion.

Pleural Effusion: There is no pleural effusion.

Aortic Valve: Aortic valve is trileaflet. There is no aortic stenosis. There is trivial aortic regurgitation.

Mitral Valve: Mitral valve is myxomatous. There is bileaflet mitral valve prolapse with the prolapse appearing most prominent at the level of A2, with a resultant eccentric posteriorly directed jet at A2-P2 region. There is moderate-severe mitral regurgitation. Mitral regurgitant volume 56 mL. Mitral regurgitant fraction 44%. There is an additional large prolapse volume of 22 mL, with a potentially severe total mitral regurgitant load of 78 mL (52%). There is no mitral stenosis.

Tricuspid Valve: Tricuspid valve leaflets are normal. Tricuspid regurgitation is present but was not (could not be) quantified. Pulmonic Valve: Pulmonic valve leaflets are normal. There is no pulmonic stenosis. There is mild pulmonic regurgitation. Pulmonic regurgitant volume 6 mL. Pulmonic regurgitant fraction 8%.

Aortic Root: The aortic root is normal in size.

Chest The thoracic aorta is normal in caliber with no evidence of aneurysm, coarctation, or dissection.

Pulmonary Artery: The main pulmonary artery is normal in size without evidence of central pulmonary emboli. The right and left pulmonary arteries are normal in size.

Core Exam

Measurements:

Volumetric Analysis:

EDV: 221 ml (LV Normal Value 95-159) ESV: 71 ml (LV Normal Value 29-58)

CO: 12.43 L/min

MASS: 87 grams (LV Normal Value 85-138)

SV 150 ml (LV Normal Value 65-110) EF 68% (LV Normal Value 59-77%)

Cardiac Output HR: 83 bpm

LV Dimensions:

Wall Thickness: Anteroseptal 0.7 cm Wall Thickness - Inferolateral 0.8 cm

LV EDD - 5.5 cm LV ESD - 3.8 cm

LA Dimension (LV Systole): Area- 2 Chamber 28 cm² Length - 2 Chamber 4.9 cm Area - 4 Chamber 42 cm²



Cardiac MR Valve Assessment Study Report

CMR 2, PATIENT May 23, 2022

Length - 4 Chamber - 6.2 cm

Volume - 204 ml

Volume Normalized - 115.3 ml/m²

RA Dimensions (RV Systole):

Area - 4 Chamber 5.0 cm²

Length - 4 Chamber - 4.8 cm

Aortic Root Dimensions:

Annulus - 2.4 cm

Sinus of Valsalva - 3.5 cm

Sinotubular Junction - 2.8 cm

Extracellular Volume Measurement:

Hematocrit: 44%

Hematocrit Date: 2022-May-31

17 Segment LV Analysis:

Segment/WM/Hyperenhancement/Interpretation

Base Anteroseptal: Normal/Hyper, None Base Inferoseptal: Normal/Hyper, None Base Inferior: Normal/Hyper, None Base Inferolateral: Normal/Hyper, None Base Anterolateral: Normal/Hyper, None

Mid Anterior: Normal/Hyper, None Mid Anteroseptal: Normal/Hyper, None Mid Inferoseptal: Normal/Hyper, None Mid Inferior: Normal/Hyper, None Mid Inferolateral: Normal/Hyper, None Mid Anterolateral: Normal/Hyper, None Apical Anterior: Normal/Hyper, None Apical Septal: Normal/Hyper, None Apical Inferior: Normal/Hyper, None Apical Lateral: Normal/Hyper, None

Apex: Normal/Hyper, None

RV Analysis:

RV Basal Anterior: Normal/Hyper, None RV Basale Inferior: Normal/Hyper, None

RV Mid: Normal/Hyper, None RV Apical: Normal/Hyper, None

Findings:

LV Scar Size (17 segment): 0%

Scan Info

Scanner:

Manufacturer: Siemens

Model: Aera

Scanner Serial Number: HMH Aera (Serial #: 152050)

Pulse Sequences: SSFP cine, 2D LGE segmented, 2D LGE single-shot, Pre-contrast T1 mapping, Post-contrast T1

mapping, Phase contrast Imaging, HASTE morphology, Bright-blood SSFP morphology,

Contrast Agent: Type--Dotarem Lot Number P368B

Expiration Date: 2026-Sep-30

Sedation Used: No Gd Concentration - 0.5 M Volume Administered: 20 ml Dosage for 0.5 M - 0.15 mmol/kg



Cardiac MR Valve Assessment Study Report

CMR 2, PATIENT May 23, 2022

Serum Creatinine - 0.8 mg/dL GFR - 78.30 ml/min/1.73 m² Creatinine Date: 2022-May-31

Setup:

Scan Type: Both
Patient Type: Oupatient
Location: OPC-Aera
Incomplete Scan: No

Reason for Scan: Other Symptoms, eval native valve(s)

Referring Physician

Attending Physician: Carlos El-Tallawi Technicians: Jonse, Jasmine M

Billing:

Patient Account

CPT Codes--75561, 75565 HCPCS Codes: A9577 ICD10 Codes: I34.0, I34.1

Additional Notes

AOFF = 72 mlPAFF = 73 ml

LVSV = 150 mlRVSV = 89 ml

Total MR RVol (mL) = LVSV - LV Forward Flow (AOFF(= 78 Total MR RF (%) = RVol/(LVSV-AR) = 52% Prolapse Volume (mL) 22 Transvalvular MR (mL) 56 Transvalvular MR RF (%) 44%

TR

TR RVol (mL) = RVSV - RV Forward Flow (PAFF) = 11 TR RF (%) = RVol/(RVSV-PR) = 13%

PR

RVol (mL) = 6 RF (%) = 8%

April 27, 2023 10:43 AM EDT

CSI Admin Staff

Electronically Signed on Studycast